Belite Bio (BLTE) CFO RSUs vest into 10,000 ordinary shares

Rhea-AI Filing Summary

Belite Bio, Inc. director and Chief Financial Officer Hao-Yuan Chuang reported a compensation-related share change. On April 21, 2026, restricted stock units granted on September 15, 2025 vested upon meeting performance criteria, delivering 10,000 ordinary shares at no stated price.

Following this RSU vesting, Chuang directly holds 205,264 ordinary shares of Belite Bio. The filing reflects an internal equity award vesting rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Chuang Hao-Yuan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Other	Ordinary Share	10,000	$0.00	--

Holdings After Transaction: Ordinary Share — 205,264 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs vested: 10,000 shares Shares held after transaction: 205,264 shares RSU grant date: September 15, 2025

3 metrics

RSUs vested 10,000 shares Restricted stock units vesting into ordinary shares on April 21, 2026

Shares held after transaction 205,264 shares Direct ordinary share holdings after RSU vesting

RSU grant date September 15, 2025 Grant date of performance-based restricted stock units

Key Terms

restricted stock units ("RSUs"), vesting, performance criteria, Form 4

4 terms

restricted stock units ("RSUs") financial

"the reporting person was granted an award of restricted stock units ("RSUs") which shall vest"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

vesting financial

"resulting in vesting of the RSUs as to 10,000 ordinary shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

performance criteria financial

"RSUs which shall vest upon satisfaction of certain performance criteria"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chuang Hao-Yuan

(Last) (First) (Middle)

12750 HIGH BLUFF DRIVE, SUITE 475

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Share	04/21/2026		J(1)		10,000(1)	A	$0(1)	205,264	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On September 15, 2025, the reporting person was granted an award of restricted stock units ("RSUs") which shall vest upon satisfaction of certain performance criteria. Such performance criteria was met on 04/21/2026, resulting in vesting of the RSUs as to 10,000 ordinary shares.

	/s/ Hao-Yuan Chuang	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Belite Bio (BLTE) report for its CFO?

Belite Bio reported that CFO and director Hao-Yuan Chuang had 10,000 restricted stock units vest into ordinary shares. The RSUs were granted in 2025 and vested after performance criteria were met on April 21, 2026.

How many Belite Bio (BLTE) shares vested for the CFO in this Form 4?

The Form 4 shows 10,000 ordinary shares for Belite Bio’s CFO, resulting from vesting of restricted stock units. These RSUs were originally granted on September 15, 2025 and vested when specified performance criteria were achieved.

Is the Belite Bio (BLTE) CFO Form 4 a stock purchase or sale?

The Form 4 does not report an open-market purchase or sale. It records vesting of 10,000 restricted stock units into ordinary shares as a compensation-related event, coded as an “other acquisition or disposition” transaction.

What are the Belite Bio (BLTE) CFO’s holdings after the RSU vesting?

After the RSU vesting, Belite Bio’s CFO directly holds 205,264 ordinary shares. This total reflects the addition of 10,000 shares that vested from previously granted restricted stock units once performance conditions were satisfied.

What triggered the vesting of Belite Bio (BLTE) CFO’s restricted stock units?

The RSUs granted to Belite Bio’s CFO on September 15, 2025 vested when specified performance criteria were satisfied. According to the filing footnote, those performance criteria were met on April 21, 2026, causing 10,000 ordinary shares to vest.